Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) announced FDA approval for its PD-L1 IHC 22C3 pharmDx assay, expanding its application to non-small cell lung cancer (NSCLC) patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50%. This diagnostic aids in identifying eligibility for treatment with Libtayo® (cemiplimab-rwlc), an anti-PD-1 therapy. Agilent's assay is the only FDA-approved companion diagnostic for this purpose, enhancing pathologist confidence in patient assessments and reinforcing Agilent's leadership in companion diagnostics for cancer therapies.
Summary not available.
Agilent Technologies Inc. (NYSE: A) has launched the Agilent Dako SARS-CoV-2 IgG ELISA kit, enabling qualitative detection of IgG antibodies to SARS-CoV-2 in human serum or plasma. This marks Agilent's entry into SARS-CoV-2 testing in the US, following FDA notification. The kit boasts an impressive 98.9% sensitivity and 98.8% specificity and includes all necessary reagents for ease of use in small to medium-sized clinical labs. Agilent aims to expand this offering globally, supporting COVID-19 management with additional tests planned, including a quantitative RT-PCR test.
Agilent Technologies Inc. (NYSE: A) has launched the Seahorse XF HS Mini Analyzer, enhancing metabolic analysis capabilities for researchers using rare and genetically engineered cells. This new device offers improved sensitivity and requires fewer cells per well, making it ideal for low respiring cell types like immune cells. As researchers focus on complex in vivo settings, the XF HS Mini promises to unlock advanced metabolic analyses, thereby increasing the utility of Agilent’s technology in disease modeling.
Agilent Technologies reported a revenue of $1.55 billion for Q1 2021, marking a 14% increase year-over-year and a 11% rise on a core basis. GAAP net income surged to $288 million (93 cents/share), up from $197 million (63 cents/share) in Q1 2020. Non-GAAP net income was $328 million (1.06/share), compared to $252 million (81 cents/share) the previous year. Agilent raised its full-year revenue outlook to $5.825 billion - $5.900 billion and announced a new $2 billion share repurchase program, effective Feb. 18.
Agilent Technologies (NYSE: A) has announced key webcasts for the investment community. The 10th Annual SVB Leerink Global Healthcare Conference is scheduled for Feb. 24 at 7:40 a.m. PT, featuring CFO Bob McMahon. Following this, the 41st Annual Cowen And Company Healthcare Conference will take place on March 4 at 8:10 a.m. PT, with President and CEO Mike McMullen presenting. Additionally, Agilent's Annual Shareholder Meeting is set for March 17 at 8 a.m. PT, with virtual access starting at 7:30 a.m. PT.
Agilent Technologies (NYSE: A) won a federal court judgement in Texas against Shanghai's J&X Technologies for patent infringement and trade secret misappropriation. J&X must pay over $1.25 million for using Agilent's proprietary gas chromatography technology. The court's ruling also prohibits J&X and its founders from manufacturing or selling related products and from disclosing Agilent's proprietary information. This victory underscores Agilent’s commitment to protecting its intellectual property as it continues to innovate in gas chromatography.
Agilent Technologies Inc. (NYSE: A) will announce its first-quarter fiscal year 2021 financial results following the market close on February 16, 2021. A live webcast of the investor conference call will take place at 1:30 p.m. Pacific time on the same day. Agilent generated $5.34 billion in revenue during fiscal year 2020 and employs approximately 16,400 individuals worldwide. The webcast will be accessible for 90 days on the company's website.
Agilent Technologies (NYSE: A) launched MassHunter Workstation Plus 11.0 and MassHunter BioConfirm, enhancing data integrity compliance with US FDA and EU EMEA standards. Key features include user management, tamper detection, and audit trails, with shipments starting in June 2021. Additionally, VWorks 14.0 Plus is introduced for the Bravo Automated Liquid Handling Platform, aiding compliance in automated sample prep. These updates solidify Agilent's position in the pharma and biopharmaceutical sectors, as highlighted by their top ranking in compliance surveys.
Agilent Technologies (NYSE: A) has appointed Allison Ballmer as the new senior vice president of Strategy and Corporate Development. Reporting to CEO Mike McMullen, Ballmer will lead merger-and-acquisition efforts and drive enterprise strategy to foster growth. With nearly 20 years in the biotech sector, including significant experience at Roche, she brings valuable expertise to Agilent's Build-and-Buy growth strategy. Agilent generated $5.34 billion in revenue in fiscal year 2020 and employs over 16,400 people globally.